吉林医学
吉林醫學
길림의학
JILIN MEDICAL JOURANL
2014年
18期
3916-3918
,共3页
支气管扩张症%肺部感染%不良反应%美罗培南
支氣管擴張癥%肺部感染%不良反應%美囉培南
지기관확장증%폐부감염%불량반응%미라배남
Bronchiectasis disease%Lung infection%Adverse reactions%Meropenem
目的:观察美罗培南治疗支气管扩张症继发肺部感染的疗效和不良反应。方法:选择51例支气管扩张症继发肺部感染的患者,随机分为两组,组1静脉滴注美罗培南(26例),组2静脉滴注头孢他啶(25例),疗程7~10 d。结果:两组支气管扩张症患者的临床有效率和细菌清除率分别为88.46%对65%,94.4%对47.06%,两组相比差异有统计学意义(P<0.05),其不良反应差异无统计学意义(P>0.05)。结论:美罗培南治疗支扩并肺部感染疗效优于头孢他定。
目的:觀察美囉培南治療支氣管擴張癥繼髮肺部感染的療效和不良反應。方法:選擇51例支氣管擴張癥繼髮肺部感染的患者,隨機分為兩組,組1靜脈滴註美囉培南(26例),組2靜脈滴註頭孢他啶(25例),療程7~10 d。結果:兩組支氣管擴張癥患者的臨床有效率和細菌清除率分彆為88.46%對65%,94.4%對47.06%,兩組相比差異有統計學意義(P<0.05),其不良反應差異無統計學意義(P>0.05)。結論:美囉培南治療支擴併肺部感染療效優于頭孢他定。
목적:관찰미라배남치료지기관확장증계발폐부감염적료효화불량반응。방법:선택51례지기관확장증계발폐부감염적환자,수궤분위량조,조1정맥적주미라배남(26례),조2정맥적주두포타정(25례),료정7~10 d。결과:량조지기관확장증환자적림상유효솔화세균청제솔분별위88.46%대65%,94.4%대47.06%,량조상비차이유통계학의의(P<0.05),기불량반응차이무통계학의의(P>0.05)。결론:미라배남치료지확병폐부감염료효우우두포타정。
Objective To observe the treatment of meropenem bronchiectasis secondary pulmonary infection curative effect and adverse reaction.MethodsSelect 51 cases of bronchiectasis Secondary pulmonary infection patients,randomly divided into two groups,group 1 drip meropenem(26 cases),group 2 drip ceftazidime(26 cases),treatment seven to ten days.ResultsTwo groups of patients with bronchiectasis clinical efficient and bacterial clearance rate were 88.46% to 65%,94.4% to 47.06%,compared with the two groups differences statistically significant difference(P<0.05),the adverse reactions there was no statistically significant difference(P>0.05).ConclusionMeropenem treatment branch expansion and lung infection curative effect is better than that of cephalosporin he shall.